

ASX Announcement

Regeneus 2015 Half-Year Results

Sydney, Australia – 19 February 2015

Regenerative medicine company, Regeneus Ltd (ASX: RGS), today reported its financial results for the half-year ended 31 December 2014.

During the 6 month period, the company made good progress on the development of its portfolio of cell-based therapies for the treatment of musculoskeletal disease and oncology conditions in humans and animals.

The financial highlights for the reporting period included:

- Revenues up 46% to \$1.14m driven by increased product and R&D licensing activities
- Net loss down 10% to \$5.75m
- Net operating cash outflows of \$1.96m reduced significantly, compared to outflows of \$3.85m during the previous half-year corresponding period
- Successful capital raising completed, net of costs of \$6.17m
- \$3.73m R&D tax incentive received
- Cash at 31 December 2014, \$6.74m
- Cash containment measures implemented (savings in excess of \$1.7m pa)

In the second-half of the financial year, the company remains focused on unlocking the value in its product portfolio with the following activities:

- partnering its clinical-stage veterinary products: Kvax, its autologous canine cancer vaccine that is in marketing trials in US and Australia; and CryoShot, its allogeneic off-the-shelf stem cell therapy for canine and equine osteoarthritis;
- commencing its first in man trials for its human products: Progenza, its allogeneic off-the-shelf stem cell therapy for human osteoarthritis; and its autologous human cancer vaccine;
- licensing HiQCell, its autologous stem cell therapy for human osteoarthritis; and
- partnering its stem cell secretions cream for the treatment of acne and other inflammatory skin conditions.

ENDS

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney-based ASX listed clinical-stage regenerative medicine company developing and commercialising a portfolio of autologous (patient's cells) and allogeneic (donor cells) cell therapies to address unmet medical needs in the human and veterinary health markets with a focus on musculoskeletal disease, oncology conditions and dermatology. Regeneus is in the clinical-stage of development of its allogeneic off-the-shelf adipose stem cell therapies for musculoskeletal disease in animals **(CryoShot)** and humans **(Progenza)**. The autologous therapeutic canine cancer vaccine **(Kvax)** is in marketing trials in Australia and the US and the human cancer vaccine is on track for a first in man trial commencing in the first half 2015.

Contact for further information:

Investors:

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au